These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15811250)

  • 1. Cholesteryl ester transfer protein TaqIB polymorphism in the cholesterol and recurrent events study.
    Marian AJ
    Curr Atheroscler Rep; 2005 May; 7(3):178-9. PubMed ID: 15811250
    [No Abstract]   [Full Text] [Related]  

  • 2. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
    de Grooth GJ; Zerba KE; Huang SP; Tsuchihashi Z; Kirchgessner T; Belder R; Vishnupad P; Hu B; Klerkx AH; Zwinderman AH; Jukema JW; Sacks FM; Kastelein JJ; Kuivenhoven JA
    J Am Coll Cardiol; 2004 Mar; 43(5):854-7. PubMed ID: 14998629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin.
    Marschang P; Sandhofer A; Ritsch A; Fiŝer I; Kvas E; Patsch JR
    J Intern Med; 2006 Aug; 260(2):151-9. PubMed ID: 16882279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
    Boekholdt SM; Sacks FM; Jukema JW; Shepherd J; Freeman DJ; McMahon AD; Cambien F; Nicaud V; de Grooth GJ; Talmud PJ; Humphries SE; Miller GJ; Eiriksdottir G; Gudnason V; Kauma H; Kakko S; Savolainen MJ; Arca M; Montali A; Liu S; Lanz HJ; Zwinderman AH; Kuivenhoven JA; Kastelein JJ
    Circulation; 2005 Jan; 111(3):278-87. PubMed ID: 15655129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
    Kuivenhoven JA; Jukema JW; Zwinderman AH; de Knijff P; McPherson R; Bruschke AV; Lie KI; Kastelein JJ
    N Engl J Med; 1998 Jan; 338(2):86-93. PubMed ID: 9420339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism of the cholesteryl ester transfer protein gene.
    Dullaart RP; van Tol A
    N Engl J Med; 1998 May; 338(22):1625-6. PubMed ID: 9606121
    [No Abstract]   [Full Text] [Related]  

  • 7. Polymorphism of the cholesteryl ester transfer protein gene.
    Goldstein MR
    N Engl J Med; 1998 May; 338(22):1624-5; author reply 1625-6. PubMed ID: 9606120
    [No Abstract]   [Full Text] [Related]  

  • 8. In search of perverse polymorphisms.
    Rosenthal N; Schwartz RS
    N Engl J Med; 1998 Jan; 338(2):122-4. PubMed ID: 9420346
    [No Abstract]   [Full Text] [Related]  

  • 9. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
    Regieli JJ; Jukema JW; Grobbee DE; Kastelein JJ; Kuivenhoven JA; Zwinderman AH; van der Graaf Y; Bots ML; Doevendans PA
    Eur Heart J; 2008 Nov; 29(22):2792-9. PubMed ID: 18957472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
    Klerkx AH; de Grooth GJ; Zwinderman AH; Jukema JW; Kuivenhoven JA; Kastelein JJ
    Eur J Clin Invest; 2004 Jan; 34(1):21-8. PubMed ID: 14984434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesteryl ester transfer protein and coronary artery disease: an observation with therapeutic implications.
    Wolfe ML; Rader DJ
    Circulation; 2004 Sep; 110(11):1338-40. PubMed ID: 15364817
    [No Abstract]   [Full Text] [Related]  

  • 12. Variations in high-density lipoprotein cholesterol in relation to physical activity and Taq 1B polymorphism of the cholesteryl ester transfer protein gene.
    Mukherjee M; Shetty KR
    Clin Genet; 2004 May; 65(5):412-8. PubMed ID: 15099350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of atherosclerosis with aggressive lipid lowering.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):86-7. PubMed ID: 15727721
    [No Abstract]   [Full Text] [Related]  

  • 14. Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study.
    Frisdal E; Klerkx AH; Le Goff W; Tanck MW; Lagarde JP; Jukema JW; Kastelein JJ; Chapman MJ; Guerin M
    Hum Mol Genet; 2005 Sep; 14(18):2607-18. PubMed ID: 16049032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of cholesteryl ester transfer protein -629C > A polymorphism with high-density lipoprotein cholesterol levels in coronary artery disease patients.
    Tanrikulu S; Ademoglu E; Gurdol F; Mutlu-Turkoglu U; Bilge AK; Nisanci Y
    Cell Biochem Funct; 2009 Oct; 27(7):452-7. PubMed ID: 19784962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can pravastatin lower coronary event rate if HDL and LDL cholesterol are at low levels?
    Maron DJ
    Nat Clin Pract Cardiovasc Med; 2004 Nov; 1(1):18-9. PubMed ID: 16265253
    [No Abstract]   [Full Text] [Related]  

  • 17. An interaction between the TaqIB polymorphism of cholesterol ester transfer protein and smoking is associated with changes in plasma high-density lipoprotein cholesterol levels in Turks.
    Hodoğlugil U; Williamson DW; Huang Y; Mahley RW
    Clin Genet; 2005 Aug; 68(2):118-27. PubMed ID: 15996208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focus on HDL as a therapeutic target for CAD risk reduction.
    Davidson MH
    Am J Cardiol; 2009 Nov; 104(10 Suppl):1E-2E. PubMed ID: 19895937
    [No Abstract]   [Full Text] [Related]  

  • 19. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of plasma cholesteryl ester transfer protein activity and polymorphism with coronary artery disease extent in Tunisian type II diabetic patients.
    Chaaba R; Hammami S; Attia N; Smaoui M; Masmoudi AS; Mahjoub S; Ben Hamda K; Hammami M
    Clin Biochem; 2005 Apr; 38(4):373-8. PubMed ID: 15766738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.